Prospective study on peripheral and intrahepatic immune cells derived from chronic hepatitis B patients during and after long-term treatment with direct antivirals - HBV-FNAB-002 study

Start Date10 Mar 2020

Sponsor / Collaborator-

100 Clinical Results associated with Antivirals(Healion Bio)

100 Translational Medicine associated with Antivirals(Healion Bio)

100 Patents (Medical) associated with Antivirals(Healion Bio)

Literatures (Medical) associated with Antivirals(Healion Bio)

01 Dec 2024·Clinical Microbiology and Infection

Re: ‘The efficacy of antivirals, corticosteroids, and monoclonal antibodies as acute COVID-19 treatments in reducing the incidence of long COVID-19’ by Sun et al.

Letter

Author: Li, Hui ; Zeng, Guangting ; Wang, Xia

A review.Sun et al. performed a systematic review and meta-anal. to evaluate the efficacy of antivirals, corticosteroids, and monoclonal antibodies as acute COVID-19 treatments in reducing the incidence of long COVID-19.Their study suggested that the use of corticosteroids during acute COVID-19 infection not only fails to prevent long COVID-19, but even slightly increases the incidence of long COVID-19 after treatment.Since the COVID-19 pandemic, there has been a clear association between dysregulation of inflammation and adverse clin. outcomes.Glucocorticoids may trigger immunosuppression and hinder viral clearance.The findings by Sun et al. could make clinicians hesitant to use glucocorticoids in patients with COVID-19.Whether glucocorticoids are involved in long COVID-19 is controversial.Here, the authors would like to highlight some points of concern and discussion.First, previous studies have demonstrated that the severity of a patient′s symptoms is related to long COVID-19.Second, the systematic review included five observational studies, which had a drawback of not considering glucocorticoid dose and duration.Third, the mechanism of long COVID-19 involves a variety of hypotheses, such as persistent viral infection, inflammation, and immune dysregulation.Thus, the accurate identification of patients with different phenotypes is the key to the rational use of glucocorticoids.

01 Dec 2024·Ophthalmology

Treatment Regimen and Outcomes in Acute Retinal Necrosis: An IRIS® Registry Study

Article

Author: Sobrin, Lucia ; Hall, Nathan ; Elze, Tobias ; Ivanov, Alexander ; Miller, Joan W ; Lains, Ines ; Gong, Dan ; Ross, Connor ; Lorch, Alice

IRIS (Intelligent Research in Sight) Registry Study showing that acute retinal necrosis cases treated with systemic antivirals alone vs combined with intravitreal antivirals or early vitrectomy had statistically similar outcomes at 6 and 12 months.

01 Dec 2024·Clinical Microbiology and Infection

‘The efficacy of antivirals, corticosteroids, and mAbs as acute COVID treatments in reducing the incidence of long COVID’ – Author’s reply

Letter

Author: Zhang, Wenhong ; Lin, Ke ; Ai, Jingwen ; Sun, Gangqiang

A polemic in response to the efficacy of antivirals, corticosteroids, and monoclonal antibodies as acute COVID treatments in reducing incidence of long COVID in patients.The following is the brief summary of our responses just to make the matter clearer: Our study never questioned the therapeutic role of corticosteroids in treating patients with acute COVID- 19, and our conclusion was that corticosteroid treatment during acute COVID has no effect on long COVID incidence.Our study suggested that more randomized controlled trial studies should be conducted in the future to provide more evidence on the relationship between corticosteroids and long COVID, and we have also emphasized the limitations of meta-anal. in this context.

100 Deals associated with Antivirals(Healion Bio)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
COVID-19	Discovery	US	Healion Bio, Inc.	01 Apr 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Antivirals(Healion Bio)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation